SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) APRIL 28, 2000
--------------
FLEMINGTON PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 000-23399 22-2407152
- --------------------------------------------------------------------------------
(STATE OR OTHER (COMMISSION (IRS EMPLOYER
JURISDICTION OF FILE NUMBER) IDENTIFICATION NO.)
FORMATION)
43 EMERY AVENUE, FLEMINGTON, NEW JERSEY 08822
- --------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (908) 782-3431
-----------------------------
N/A
- --------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGES SINCE LAST REPORT)
- --------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
On April 28, 2000, the Company announced that it had closed a private
placement of 2,000,000 shares of its common stock, receiving proceeds of
$1,000,000.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits.
(i) Press Release dated April 28, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly authorized and caused the undersigned to sign this
Report on the Registrant's behalf.
FLEMINGTON PHARMACEUTICAL
CORPORATION
By: /s/ HARRY A DUGGER, III
----------------------------
Harry A. Dugger, III
President
Dated: May 2, 2000
FOR IMMEDIATE INFORMATION, CONTACT:
Sharon Will, Investor Relations
FLEMINGTON PHARMACEUTICAL CORPORATION
Phone: 212-572-0762 Fax: 212-572-0764
Email: [email protected]
FOR IMMEDIATE RELEASE
FLEMINGTON PHARMACEUTICAL CORPORATION
ANNOUNCES PRIVATE PLACEMENT
FLEMINGTON, NEW JERSEY, April 28, 2000 - Flemington Pharmaceutical Corp.
("Flemington" or "the Company") (OTCBB: FLEM, FLEMw) announced today that it has
closed a private placement of 2,000,000 investment shares of its common stock,
receiving proceeds of $1,000,000.
Dr. Harry A. Dugger III, President & CEO of the Company stated that the proceeds
of this placement would be used primarily for the purpose of completing a number
of efficacy studies on the Company's lingual spray formulations to facilitate
the licensing of these products.
Visit our web site: www.flemington-pharma.com for further information.
-------------------------
Flemington Pharmaceutical Corp. is engaged in the development of novel
application drug delivery systems for presently marketed prescription and
over-the-counter drugs. The novel delivery systems include lingual sprays and
gelatin bite capsules. The Company believes that these delivery systems offer
(i) improved drug safety by reducing the required drug dosage, therefore,
reducing the side effects; (ii) improved dosage reliability; (iii) improved
patient convenience and compliance; and (iv) enhanced dosage reliability. The
Company plans to develop such products through collaborate arrangements with
major pharmaceutical companies.
Note: Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein. Further, the
Company operates in industries where securities may be volatile and may be
influenced by regulatory and other factors beyond the Company's control.
Important factors that the Company believes might cause such differences are
discussed in the risk factors detailed in the Company's most recent Form 10-KSB,
dated November 1, 1999, filed with the Securities and Exchange Commission; a
copy of that Form 10-KSB is available from the Company upon request. In
assessing forward-looking statements contained herein, if any, reader is urged
to carefully read all cautionary statements contained in that filing with the
Securities and Exchange Commission.
